The scatter factor/hepatocyte growth factor: c-Met pathway in human embryonal central nervous system tumor malignancy

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9355-9362

  Li, Yunqing ^a,b   Lal, Bachchu ^a,b   Kwon, Sherwin ^b   Fan, Xing ^a   Saldanha, Usha ^a   Reznik, Thomas E ^b   Kuchner, Eric B ^a   Eberhart, Charles ^a   Laterra, John ^a,b   Abounader, Roger ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P27; SCATTER FACTOR; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR C MET; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL PROTECTION; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; GENE TRANSFER; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HEPATOCYTE GROWTH FACTOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEDULLOBLASTOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 27144524893     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1946     Document Type: Article

References (46)

1. Reddy AT, Packer RJ. Medulloblastoma. Curr Opin Neurol 1999;12:681-5.
2. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002;28:257-82.
3. Taylor MD, Mainprize TG, Rutka JT. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 2000;47:888-901.
4. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001;24: 385-428.
5. Packer RJ. Brain tumors in children. Arch Neurol 1999;56:421-5.
6. Newton HB. Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma. Expert Opin Investig Drugs 2001;10: 2089-104.
7. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
8. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996;119:591-600.
9. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
10. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001;153:1023-34.
11. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997;21:11445-50.
12. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109:863-7.
13. Laterra J, Nam M, Rosen E, Rao JS, Johnston P. Scatter factor/hepatocyte growth factor gene transfer to 9L glioma cells enhances glioma growth and angiogenesis in vivo. Lab Invest 1997;76:565-77.
14. Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 1999;91:1548-56.
15. Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002;16:108-10.
16. Bowers DC, Fan S, Walter K, et al. Scatter factor/hepatocyte growth factor activates AKT and protects against cytotoxic death in human glioblastoma via PI3-kinase and AKT-dependent pathways. Cancer Res 2000;60:4277-83.
17. 1 c-Myc dependent, and independent of p27 suppression cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol 2002;22:2703-15.
18. Lamszus K, Liang J, Laterra J, et al. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer 1998;75:19-28.
19. Lamszus K, Laterra J, Westphol M, Rosen EM. Scatter factor/hepatocyte growth factor content and function in human gliomas. Int J Dev Neurosci 1999;17:517-30.
20. Schmidt MO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relationship to angiogenesis. Int J Cancer 1999;84:10-8.
21. Rosen EM, Goldberg ID. Regulation of angiogenesis by scatter factor. Basel (Switzerland): Birkhäuser Verlag; 1997.
22. Tanimura S, Chantani Y, Hoshino R, et al. Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene 1998;17:57-65.
23. Sipeki S, Bander E, Buday L, et al. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal 1999;11:885-90.
24. Graziani A, Gramaglia D, Cantley LC, Comoglio PM. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 1991;266:22087-90.
25. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signalling and transformation by the HGF/SF receptor family. Cell 1994;77:261-71.
26. Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 2001;98:247-52.
27. Fan S, Ma YX, Wang J, et al. The cytokine scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase. Oncogene 2000;19:2212-23.
28. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:2050-4.
29. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997;11:1464-78.
30. Fan X, Wang Y, Kratz J, et al. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol 2003;162:1763-9.
31. Abounader R, Ranganathan S, Kim BY, Nichols C, Laterra J. Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. J Neurochem 2001;76:1497-508.
32. Yamada M, Shimizu K, Tamura K, et al. [Establishment and biological characterization of human medulloblastoma cell lines]. No To Shinkei 1989;41:695-702.
33. Yamada M, Shimizu K, Tamura K, et al. Murine model of leptomeningeal dissemination using human medulloblastoma cells. Neurol Med Chir (Tokyo) 1991;31:763-7.
34. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52.
35. He XM, Skapek SX, Wikstrand CJ, et al. Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropathol Exp Neurol 1989;48:48-68.
36. Wikstrand CJ, Friedman HS, Bigner DD. Medulloblastoma cell-substrate interaction in vitro. Invasion Metastasis 1991;11:310-24.
37. Fults D, Pedone CA, Morse HG, Rose JW, McKay RD. Establishment and characterization of a human primitive neuroectodermal tumor cell line from the cerebral hemisphere. J Neuropathol Exp Neurol 1992;51:272-80.
38. Hossain MA, Bailone JC, Gomes R, Laterra J. Neuroprotection by scatter factor/hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/Akt-dependent and MAPK/CREB-independent. J Neurochem 2002;81:365-78.
39. Duplan SM, Theoret Y, Kenigsberg RL. Antitumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant. Clin Cancer Res 2002;8:246-57.
40. Kim JY, Sutton ME, Lu DJ, et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999;59:711-9.
41. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001;169:107-14.
42. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 1994;91:12867-71.
43. Kenigsberg RL, Hong Y, Yao H, et al. Effects of basic fibroblast growth factor on the differentiation, growth, and viability of a new human medulloblastoma cell line (UM-MB1). Am J Pathol 1997;151:867-81.
44. Gilbertson RJ, Clifford SC, MacMeekin W, et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res 1998;58: 3932-41.
45. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 upregulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003;63:140-8.
46. Lal B, Xia C, Abounader R, Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to γ-radiation. Clin Cancer Res 2005;11:4479-86.